Image source: Getty Images.
After reporting positive phase 3 trial results for its glaucoma drug Roclatan and upping the size of a planned equity offering to $75 million, shares in Aerie Pharmaceuticals (NASDAQ: AERI) are climbing 11.9% at 3:30 p.m. EDT today.